

CLAIMS

1. (Canceled)

5 2. (Canceled)

3. (Canceled)

4. (Canceled)

10

5. (Canceled)
6. (Canceled)
- 5 7. (Canceled)
8. (Canceled)
9. (Canceled)
- 10 10. (Canceled)
11. (Canceled)
- 15 12. (Canceled)

13. (Canceled)

14. (Canceled)

5 15. (Canceled)

16. (Canceled)

17. (Canceled)

10 18. (Canceled)

19. (Canceled)

15 20. (Canceled)

21. (Canceled)

22. (Canceled)

5 23. (Canceled)

24. (Canceled)

25. (Canceled)

10 26. (Canceled)

27. (Canceled)

15 28. (Canceled)

29. (Canceled)

30. (Canceled)

5 31. (Canceled)

32. (Canceled)

1 33. (Added) An expression vector,
which comprises: (a) a first coding region encoding
5 PPIase having molecular chaperone activity, and
(b) a region having at least one restriction enzyme
site in which a second coding region encoding a desired
protein can be inserted.

10 2 34. (Added) The expression vector according to claim
33,

wherein the first coding region is operatively
linked to a promoter, and the restriction enzyme site is
in the same reading frame as the first coding region, and
15 is downstream of the first coding region.

3 35. (Added) The expression vector according to claim
33 or 34,

which has a region being between a first coding
20 region and a region having at least one restriction enzyme
site in which a second coding region can be inserted, and
is translated in the same reading frame to be a protease
digestion site.

25 4 36. (Added) An expression vector,

wherein a second coding region encoding a desired
protein is inserted into the expression vector according
to claim 33, 34 or 35.

30 5 37. (Added) The expression vector according to claim
33, 34, 35 or 36,

wherein the PPIase having molecular chaperone
activity is FKBP-type PPIase.

6 38. (Added) The expression vector according to claim
33, 34, 35 or 36,

wherein the PPIase having molecular chaperone
activity is cyclophilin-type PPIase.

5

7 39. (Added) The expression vector according to claim
33, 34, 35 or 36,

wherein the PPIase having molecular chaperone
activity is parvulin-type PPIase.

10

4 40. (Added) The expression vector according to claim
37,

wherein the FKBP-type PPIase is archaebacterial
FKBP-type PPIase.

15

9 41. (Added) The expression vector according to claim
40,

wherein the archaebacterial FKBP-type PPIase is
short type FKBP-type PPIase.

20

10 42. (Added) The expression vector according to claim
33, 34, 35, 36, 37, 38 or 39,

wherein the PPIase having molecular chaperone
activity comprises an IF domain and/or a C-terminal domain
25 of archaebacterial FKBP-type PPIase.

11 43. (Added) The expression vector according to claim
37,

wherein the FKBP-type PPIase is trigger factor-type
30 PPIase.

12 44. (Added) The expression vector according to claim
33, 34, 35, 36, 37, 38 or 39,

wherein the PPIase having molecular chaperone
35 activity comprises a N-terminal domain and/or a C-terminal

domain of trigger factor-type PPIase.

45. (Added) The expression vector according to claim 37,

5 wherein the FKBP-type PPIase is FkpA-type PPIase.

46. (Added) The expression vector according to claim 33, 34, 35, 36, 37, 38 or 39,

10 wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of FkpA-type PPIase.

47. (Added) The expression vector according to claim 37,

15 wherein the FKBP-type PPIase is FKBP52-type PPIase.

48. (Added) The expression vector according to claim 33, 34, 35, 36, 37, 38 or 39,

20 wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of FKBP52-type PPIase.

49. (Added) The expression vector according to claim 38,

25 wherein the cyclophilin-type PPIase is CyP40-type PPIase.

50. (Added) The expression vector according to claim 33, 34, 35, 36, 37, 38 or 39,

30 wherein the PPIase having molecular chaperone activity comprises a C-terminal domain of CyP40-type PPIase.

51. (Added) The expression vector according to claim 39,

35 wherein the parvulin-type PPIase is SurA-type PPIase.

1^o 52. (Added) The expression vector according to claim 33, 34, 35, 36, 37, 38 or 39,

5 wherein the PPIase having molecular chaperone activity comprises a N-terminal domain of SurA-type PPIase.

1^o 53. (Added) The expression vector according to claim 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 or 52,

10 wherein the second coding region has a nucleotide sequence encoding a monoclonal antibody.

1^o 54. (Added) The expression vector according to claim 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 15 51 or 52,

wherein the second coding region has a nucleotide sequence encoding a membrane protein.

1^o 55. (Added) A host,

20 which contains the expression vector according to claim 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53 or 54.

1^o 56. (Added) The host according to claim 55,

25 which is Escherichia coli.

1^o 57. (Added) A fused protein,

which comprises PPIase having molecular chaperone activity and a desired protein.

30

1^b 58. (Added) The fused protein according to claim 57, which comprises a protease digestion site between PPIase having molecular chaperone activity and a desired protein.

59. (Added) A process for producing a fused protein comprising PPIase having molecular chaperone activity and a desired protein,

which comprises making the expression vector
5 according to claim 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 53 or 54 express the fused
protein.

60. (Added) The process for producing a fused
10 protein according to claim 59,

which comprises culturing the host containing the
expression vector under condition of expression of the
expression vector, and making express the fused protein in
a cytoplasm.

15

61. (Added) The process for producing a fused
protein according to claim 59,

which comprises providing a region being transcribed
and translated to be a signal sequence at a 5' terminus of
20 a first coding region or a 5' terminus of a second coding
region of the expression vector, and culturing a host
containing the expression vector under condition of
expression of the expression vector to express the fused
protein in a periplasm or a medium.

25

62. (Added) The process for producing a fused
protein according to claim 59,

which comprises making the expression vector express
the fused protein in a cell-free translation system.

30

63. (Added) The process for producing a fused
protein according to claim 59, 60, 61 or 62,

wherein the fused protein is adsorbed on a carrier
harboring macrolide, cyclosporin, juglone or its analogous
35 compound inhibiting PPIase activity, and then the carrier

is recovered and the fused protein is recovered from the carrier.

7 64. (Added) A process for producing a desired
5 protein,

which comprises digesting the fused protein comprising a protease digestion site obtained by the process according to claim 59, 60, 61, 62 or 63 with a protease digesting a protease digestion site.